BridgeBio Oncology Therapeutics (BBOT) Long-Term Debt Issuances (2024)
BridgeBio Oncology Therapeutics (BBOT) posted Long-Term Debt Issuances of $209853.0 for Q1 2024.
BridgeBio Oncology Therapeutics (BBOT) Long-Term Debt Issuances (2024) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Long-Term Debt Issuances for 1 years, with the latest figure at $209853.0 in Q1 2024.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to $209853.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $209853.0 (changed N/A YoY) and the FY2024 annual result came in at $209853.0, changed N/A from the prior year.
- Long-Term Debt Issuances was little changed at $209853.0 in Q1 2024 per BBOT's latest filing.
- Over five years, Long-Term Debt Issuances peaked at $209853.0 in Q1 2024 and troughed at $209853.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -675,522.58 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 209,853.00 |
| Mar 31, 2024 | 209,853.00 |